Previous close | 0.0300 |
Open | 0.2100 |
Bid | 0.0000 |
Ask | 4.3000 |
Strike | 195.00 |
Expiry date | 2024-05-17 |
Day's range | 0.0300 - 0.2100 |
Contract range | N/A |
Volume | |
Open interest | 147 |
Eli Lilly stock broke out and then retreated into sell-zone territory. With shares on the rise again, is LLY stock a buy?
Biogen stock jumped early Wednesday after the FDA gave its Eisai-partnered Alzheimer's treatment a fast track designation.
Eisai and partner Biogen said on Tuesday that the Japanese drugmaker has begun submitting data on a rolling basis to the US health regulator for a marketing application of a subcutaneous form of their Alzheimer's disease drug Leqembi. The companies are seeking the Food and Drug Administration's (FDA) approval of a weekly dose of Leqembi to be given as an under-the-skin injection. Under a rolling submission the regulator assesses the data as and when it becomes available, and the process continues until there is enough data for a formal marketing application.